How to buy Nevro stock | $161.99

Nevro Corp is a medical devices business based in the US. Nevro shares (NVRO) are listed on the NYSE and all prices are listed in US Dollars. Nevro employs 853 staff and has a trailing 12-month revenue of around USD$366.7 million.

How to buy shares in Nevro

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Nevro. Find the stock by name or ticker symbol: NVRO. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Nevro reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$161.99, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Nevro, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Nevro. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Nevro share price

Use our graph to track the performance of NVRO stocks over time.

Nevro shares at a glance

• Key figures

Information last updated 2020-12-07.

Latest market close	USD$161.99
52-week range	USD$65.05 - USD$175.71
50-day moving average	USD$161.3515
200-day moving average	USD$139.7534
Wall St. target price	USD$174.58
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.064

Buy Nevro shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Nevro stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Nevro Corp by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nevro price performance over time

Historical closes compared with the close of $161.99 from 2020-12-09

1 week (2021-01-12)	N/A
1 month (2020-12-23)	-12.12%
3 months (2020-10-19)	N/A
6 months (2020-07-19)	N/A

1 year (2020-01-19)	N/A
2 years (2019-01-19)	N/A
3 years (2018-01-19)	N/A
5 years (2016-01-19)	N/A

Nevro financials

Revenue TTM	USD$366.7 million
Gross profit TTM	USD$268.4 million
Return on assets TTM	-7.35%
Return on equity TTM	-31.04%
Profit margin	-24.46%
Book value	$11.034
Market capitalisation	USD$5.5 billion

TTM: trailing 12 months

Shorting Nevro shares

There are currently 2.6 million Nevro shares held short by investors – that's known as Nevro's "short interest". This figure is 4.2% up from 2.5 million last month.

There are a few different ways that this level of interest in shorting Nevro shares can be evaluated.

Nevro's "short interest ratio" (SIR)

Nevro's "short interest ratio" (SIR) is the quantity of Nevro shares currently shorted divided by the average quantity of Nevro shares traded daily (recently around 311474.87864078). Nevro's SIR currently stands at 8.24. In other words for every 100,000 Nevro shares traded daily on the market, roughly 8240 shares are currently held short.

However Nevro's short interest can also be evaluated against the total number of Nevro shares, or, against the total number of tradable Nevro shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nevro's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Nevro shares in existence, roughly 70 shares are currently held short) or 0.0856% of the tradable shares (for every 100,000 tradable Nevro shares, roughly 86 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nevro.

Find out more about how you can short Nevro stock.

Nevro share dividends

We're not expecting Nevro to pay a dividend over the next 12 months.

Have Nevro's shares ever split?

Nevro's shares were split on a 1:24 basis on 6 November 2014. So if you had owned 24 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nevro shares – just the quantity. However, indirectly, the new 2300% higher share price could have impacted the market appetite for Nevro shares which in turn could have impacted Nevro's share price.

Nevro share price volatility

Over the last 12 months, Nevro's shares have ranged in value from as little as $65.05 up to $175.71. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Nevro's is 0.9879. This would suggest that Nevro's shares are less volatile than average (for this exchange).

Nevro overview

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. It also offers Senza II system and Senza Omnia system products for chronic pain. The company's solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Nevro Corp. sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was founded in 2006 and is headquartered in Redwood City, California.

Frequently asked questions

• What percentage of Nevro is owned by insiders or institutions?

  Currently 1.994% of Nevro shares are held by insiders and 108.104% by institutions.

• How many people work for Nevro?

  Latest data suggests 853 work at Nevro.

• When does the fiscal year end for Nevro?

  Nevro's fiscal year ends in December.

• Where is Nevro based?

  Nevro's address is: 1800 Bridge Parkway, Redwood City, CA, United States, 94065

• What is Nevro's ISIN number?

  Nevro's international securities identification number is: US64157F1030

• What is Nevro's CUSIP number?

  Nevro's Committee on Uniform Securities Identification Procedures number is: 64157F103